key: cord-0983063-gf88v9cr
authors: Ayipo, Yusuf Oloruntoyin; Yahaya, Sani Najib; Alananzeh, Waleed A.; Babamale, Halimah Funmilayo; Mordi, Mohd Nizam
title: Pathomechanisms, therapeutic targets and potent inhibitors of some beta-coronaviruses from bench-to-bedside
date: 2021-05-28
journal: Infect Genet Evol
DOI: 10.1016/j.meegid.2021.104944
sha: 7bb5d71777268b1a7057335f3eb11d475a52b1d6
doc_id: 983063
cord_uid: gf88v9cr

Since the emergence of their primitive strains, the complexity surrounding their pathogenesis, constant genetic mutation and translation are contributing factors to the scarcity of a successful vaccine for coronaviruses till moment. Although, the recent announcement of vaccine breakthrough for COVID-19 renews the hope, however, there remains a major challenge of accessibility to urgently match the rapid global therapeutic demand for curtailing the pandemic, thereby creating an impetus for further search. The reassessment of results from a stream of experiments is of enormous importance in identifying bona fide lead-like candidates to fulfil this quest. This review comprehensively highlights the common pathomechanisms and pharmacological targets of HCoV-OC43, SARS-CoV-1, MERS-CoV and SARS-CoV-2, and potent therapeutic potentials from basic and clinical experimental investigations. The implicated targets for the prevention and treatment include the viral proteases (M(pro), PL(pro), 3CL(pro)), viral structural proteins (S- and N-proteins), non-structural proteins (nsp 3, 8, 10, 14, 16), accessory protein (ns12.9), viroporins (3a, E, 8a), enzymes (RdRp, TMPRSS2, ADP-ribosyltransferase, MTase, 2’-O-MTase, TATase, furin, cathepsin, deamidated human triosephosphate isomerase), kinases (MAPK, ERK, PI3K, mTOR, AKT, Abl2), interleukin-6 receptor (IL-6R) and the human host receptor, ACE2. Notably among the 109 overviewed inhibitors include quercetin, eriodictyol, baicalin, luteolin, melatonin, resveratrol and berberine from natural products, GC373, NP164 and HR2P-M2 from peptides, 5F9, m336 and MERS-GD27 from specific human antibodies, imatinib, remdesivir, ivermectin, chloroquine, hydroxychloroquine, nafamostat, interferon-β and HCQ from repurposing libraries, some iron chelators and traditional medicines. This review represents a model for further translational studies for effective anti-CoV therapeutic designs.

similar pathology and pathomechanisms, a large range of prospective candidates are being experimented against the old and newly emerged strains. Many of these agents demonstrate strong inhibitory potentials across the strains at various experimental levels, a propensity for effective therapeutic development for the current and emerging CoVs. Although, some reports have been recently documented with a specific overview on either the therapeutic target or the class of inhibitors [22] [23] [24] . However, an all-inclusive analysis of homologous human CoV strains from features through infection to treatment remains sparse. This review comprehensively highlights the common pathomechanisms and pharmacological targets of four beta-CoVs infectious to human, HCoV-OC43, SARS-CoV-1, MERS-CoV and SARS-CoV-2, and potential therapeutic candidates from the recently reported basic and clinical experimental investigations.

The understanding of the structural characteristics is essential for speedy approaches towards therapeutic development including structure-assisted drug design, high throughput screening [19, 25] . Similarly, a clinical case study indicates the complications of SARS-CoV-2-related syndrome with ARDs and diagnosed cardiac injury expressed as myocarditis, stress cardiomyopathy and demand ischemia, thereby inclusively implicating the interleukin-6 and aldose reductase as pathophysiological targets [26] . Due to these complications, the J o u r n a l P r e -p r o o f applications of the ACE-2 inhibitors, renin-angiotensin-aldosterone system (RAAS) inhibitors and/or angiotensin receptor blockers (ARBs) in the experimental trials of SARS-CoV prevention and treatment creates a scientific argument [27] . Some researchers suggest the discontinuation of ACE inhibitors and ARBs in the therapeutic trials based on the hypothesis that they facilitate SARS-CoV-2 diffusion into cells, thereby contributing to the severity, others claim there exist no basic or clinical experimental shreds of evidence to support the argument, as such they are recommended for continuous applications [28] [29] [30] [31] . In addition to the ACE2, sometimes the FURIN gene, a paired basic amino acid cleaving enzyme located on chromosome 15, performs relevant pathophysiological functions. Thus, its repressors/silencers are putatively identified as markers for mitigating the viral entry [32] .

Furthermore, the viral main proteases (M pro ) and chymotrypsin-like proteases (3C/3CL pro ) and papain-like proteases (PL pro ) are important enzymes which play pivotal roles in mediating replication and transcription, usually through the cleavage of viral polyprotein into intermediate or fully developed new virus proteins, thus constitute essential therapeutic targets [14, 33] . Other structural features include the nucleocapsid (N) phosphoprotein, the structural entities essentials for the formation of the RNP-enclosed virion particles for viral infection [34] . This protein encodes the viral genome into a helical structure, ribonucleocapsid protein (RNP) and plays essential parts in the viral multifarious activities including self-assembly.

There are only 600-1500 chemotherapeutic targets originally encoded by the human genome for small molecule drugs, but posttranslational modifications make the druggable targets considerably larger [35] . However, CoVs exceptionally to other RNA viruses, possess a large genome associated with low rates of mutation. All CoVs contain a conserved macrodomain non-structural protein 3 (nsp 3) which enzymatically detaches the covalently bonded adenosine diphosphate (ADP)-ribose from protein targets, thereby reversing the ADP-J o u r n a l P r e -p r o o f ribosyltransferase activity and immune innate response. This indicates the possibility of ADP-ribosylation in the pathogenic CoV virulence factor and the potential of the enzyme as a target for vaccine development [36] . The CoVs also code for nsp14, a bifunctional enzyme with RNA cap guanine N-7-methyltransferase (MTase) and 3'-5' exoribonucleic (ExoN) activities, thereby making it a potential therapeutic target. The translation and stability of the RNA are greatly influenced by the 5'cap structures of the eukaryotic messenger RNA (mRNA) in most viruses with replication occurring in the cytoplasm of eukaryotes which releases 2'-O-MTase for mRNA modification through the m7GppNm 5'-cap formation. The mechanisms enhance the replication and an escape to innate immune recognition within the host cells. However, these resistance-inclined processes require the stimulation of the 2'-O-MTase activity of SARS-CoV nsp16 by nsp10. Unarguably, the nsp16/nsp10 2'-O-MTase activation is thus, an important therapeutic target for overcoming viral replication and innate resistance. The expression was demonstrated in vitro using a biochemical assay for MTase activity, while a peptide, TP29 derived from the nsp16/nsp10 domain shows great experimental inhibition of the pathway [12, 37] . Similar to these are the ns12.9 accessory proteins which function as a viroporin and are reportedly involved in the pathogenesis and morphogenesis of virion in HCoV-OC43 [38] . Also reported is the nsp8 which participates in diverse non-canonical template-dependent polymerase activities including the metal iondependent RNA 3'-terminal adenylyl transferase (TATase) activity for viral replication in HCoV-229E [39] .

The viroporins are viral proteins associated with ion channel activity, stimulation of viral release from infected cells, and are essential for virulence pathogenesis and replication. The SARS-CoVs encode 3a, E and 8a viroporins. Whilst the 3a and E are actively involved in the control of various cell functions including replication and pathogenesis due to the presence of PDZ-binding motif (PBM), a potential for binding over 400 cellular proteins with PDZ unique domain (SUD) consisting of the C, M and N macrodomains are possible targets for Gquadruplet binding activity. As experimental evidence, chemokine analysis indicates that the SUD actuated the nucleotide-binding oligomerisation domain, leucine-rich-repeat and pyrin domain-containing protein 3 (NLRP3) inflammasome-dependent C-X-C motif chemokine ligand 10 (CXCL10)-mediated pulmonary inflammation, confirmed by NLRP3 inflammasome inhibitor in a mouse model (Fig. 3 ) [51] . The deamidated human triosephosphate isomerase, a glycolytic enzyme was demonstrated as another promising druggable target for the prevention/treatment of SARS-CoV-2 infection using in silico and in vitro experimental assays [35] .

Possibly arising from their evolutional differentiation, the four strains of coronaviruses under focus, HCoV-OC43, SARS-CoV-1, MERS-CoV and SARS-CoV-2 have been resolved with genomic and structural homology especially at the active sites of their main therapeutic targets, the NTD of N-protein (Fig. 4) [45] , the S-protein at the 6-HB fusion core (Fig. 5) [42, 52] , 3CL pro [53] and the PL pro [54] . This structural homology further unveils the underlying similarity in their molecular mechanisms of infection, pharmacological pathways and therapeutic hypotheses. Further analyses suggest the inhibitory mechanisms against the essential proteases for proteolytic activities of viral polyproteins as a common therapeutic pathway against the CoVs [54] .

The emergencies usually associated with CoV outbreaks warrant reasonable therapeutic CoV-2, and this led to the suggestion of some KD suppressors such as the serum interferongamma (IFNγ) and interleukin 6 (IL-6) with diminishing inflammatory cytokine mechanisms as adjuvant treatments [55] . Impressive antiviral activities of some phytochemicals such as saikosaponins which include the inhibition of influenza virus and several inflammatory mediators such as reactive oxygen species (ROS), cyclooxygenase-2 (COX-2) and the interleukins (IL-6, IL-8, IL-10) mainly prompted their suggestive trials during the first wave of COVID-19 [56] . In a commentary reported by Bleasel and Peterson, emetine, an alkaloid from ipecacuanha root demonstrates stronger inhibitory potentials against MERS-CoV and SARS-CoV-1 in 500-2000-folds of the effect against Entamoeba histolytica, its main target as anti-amoebiasis. Although the treatment is associated with emetic complications in patients, it is manageable with 5-HT 3 antagonists such as ondansetron. It is therefore suggested to deliver emergent therapeutic demand against COVID-19 [57] . Clinical impediments of neuroinvasive and neurotropic effects have been reportedly observed in association with COVID-19 in forms of neurological symptoms such as hyposmia, anosmia and dysgeusia, indicating the applicability of doxycycline in treatment studies [58] .

Chloroquine (CQ) and its derivative, hydroxychloroquine (HCQ) are among the most popular inhibitors of enveloped viruses such as dengue, Nipah and Hendra paramyxoviruses, human immunodeficiency virus (HIV) and the CoVs in vitro through the hijacking of the endocytic pathway, the process in which the endosomal lipid, bis(monoacylglycero)phosphate reportedly plays a vital role. Other suggested mechanisms of chemotherapeutic actions of these weak bases include the increment in the lysosomal pH through the alkylation of phagolysosome, inhibition of glycosylation, interference with the virus-receptor binding and proliferation, and inhibition of the acidic proteases that are responsible for the maturation of viral fusion proteins [59] [60] [61] . Although, with limited experiments, the in vivo efficacy is J o u r n a l P r e -p r o o f strongly debated still, however, it is earmarked as early therapeutic targets for SARS-CoV treatment [59] . Other therapeutic hypotheses for clinical investigation include teicoplanin, a glycopeptide antibiotic for treating several bacterial infections [62] , heparin, an antiinflammation agent [63] , mevalonate pathway inhibitors and statins owing to their antiinflammatory and immunomodulatory effects which benefit patients suffering from viral pathology such as influenza [64] . From the reported activities, these bioactive agents are hypothesized to possess potentials for improving prognosis in coronavirus pathologies.

Since the similarities in pathophysiologies and the protein residual sequencing (especially at the active sites) of the existing and emerging CoV strains support the hypothesis of similar pathomechanisms of infection, similar approaches could be rationally employed for their prevention and treatment [42] , which have been virtually demonstrated [42, 65, 66] . From experimental studies, the inhibition of the 3CL pro and the PL pro have been documented for lopinavir, although experimental arguments favour its inhibition of HIV protease more [67] .

The S-protein and ACE2 by arbidol, viral RNA-dependent RNA polymerase (RdRp) by remdesivir and ribavirin, TMPRSS2 by camostat mesylate and ACE2 glycosylation by CQ analogues [68] . Other conventional medications known for the mitigation of ARDS, influenza, acute lung injury (ALI), inflammation, hypertension, immunomodulation have also been evaluated against pandemics, including losartan, statins and ARBs [12, 69] . Improved immune responses in SARS-CoV and MERS-CoV infected patients have also been investigated upon administration of chemokine and cytokine modulators such as tocilizumab and the human mesenchymal cells [70] [71] [72] .

Among the herbal medicines screened, respiratory detox shot and Shuanghuanglian oral liquid, traditional Chinese medicines with known antiviral history experimented in early J o u r n a l P r e -p r o o f prevention and control of COVID-19 through inhibition of SARS-CoV-2's 3CL pro , PL pro , spike protein etc by theoretical binding and in vitro studies [73, 74] . The Xeubijing injection was also demonstrated with the active expression of the inflammatory response and lung injury, indicated by the improvement on lymphocyte count, partial pressure of CO 2 in the artery and oxygenation index in patients with critical complicated conditions of COVID-19 [75] . Similarly, the Liu Shen capsule, Lianhuaqingwen and Gene-Eden-Vir/Novirin have been reported with inhibitory potential against SARS-CoV-2 through the regulation of innate immune response, inhibition of cell entry and replication, inhibition of viral proteases and reduction in pro-inflammatory cytokines [76] [77] [78] .

The natural product, melatonin is a protective agent against some pathogenesis associated with viral infections and ARDS has also been speculated as an adjuvant in the treatment of some chronic ailments induced by COVID-19 including ARDS, ALI and pneumonia [18] .

Other phytochemicals such as theaflavin, quercetin, baicalin, berberine, eriodictyol, lycorine etc with experimental antiviral potency have also been reviewed among the currently available options for further studies [79] .

Sometimes the inhibitors are in the form of antibodies which could mediate through prophylactic therapeutic development and monoclonal immunotherapies. For instance, the monoclonal antibody (mAb), 5F9 binds to the NTD of MERS-CoV at the S1 subunit as a neutralising epitope, thereby mapping the S-protein for viral infusion [6] , and the murine antisera which reportedly neutralised the MERS-CoV activity in vitro and in vivo basic and clinical experimental models [80] . The overview of these important therapeutic innovations is comprehensively addressed according to the CoV strain targets as follows.

Shen and co-researchers performed an HTS assay on 2000 approved drugs out of which 56 hits were retrieved. Upon further biochemical analysis against the wild type CoV strains, seven repurposing drugs, 1 -7 (Scheme 1) were identified with strong inhibition against the viral replications of HCoV-OC43 and MERS-CoV in vitro at low EC 50 and CC 50 values of <5 and >20 µM respectively. The further evaluation shows that 1 protected the BALB/c mice from the lethality of HCoV-OC43 as observed using novel RT bioluminescence imaging for monitoring HCoV-OC43 distribution in vivo mice while 2 blocked the entry of MERS-CoV [81] . These compounds especially, 1 and 2 are therefore recommended as potential therapeutics against CoV entry and replication upon further study.

The HCoV-OC43 on emergence was pinpointed as the major cause of common cold and upper respiratory tract infections with resistance to several available drugs [82] . Owing to this speculation, Shen and co-workers developed four recombinants HCoVs-OC43 expressing the Renilla luciferase (Rluc) receptor gene. They demonstrated that the HCoV-OC43 replication was strongly inhibited by 8 in higher terms than 9 in vitro with an inhibitory concentration (IC 50 ) value of 0.33 µM and 10 µM respectively (Scheme 1). The adopted assays include Rluc activity, dual-luciferase reporter, small interfering RNA screening (siRNA), a doublestranded, non-coding RNA molecule with a length comprising of 20-25 base pairs, Western blot and antiviral assays. Other experimental protocols include cell viability assay using BHK-21, Huh and HEK-293T cell lines, and in vivo mice model [82] . 

In similitude to the report of Shen The dipeptidyl, 20 were further investigated for safety, pharmacokinetics and 3CL pro -targeted efficacy in vivo FIP virus-infected cats. The experimental fatality of the cats was 100% once the clinical indications become obvious after the infection. Upon treatment with 20, the cats fully recover from the associated ailments such as fever, weight loss, lymphopenia, ascites, jaundice (mucous membrane/plasma) and other signatory illnesses, then regain normal healthy lives within 20 days of treatment (Table 2 ) [87] . Although, the increase in the rate of recovery with the treatment duration supports the continuous administration for effective recovery, however, the compound interestingly worth further translational study as inhibitory therapeutics against CoV infections targeting the 3CL pro pathways.

Mucroporin-M1 (32), a highly penetrating defensive peptide from the scorpion venom with amino sequence LRFLIKSLIKRLVSAFK reportedly exhibit remarkable virucidal effects against SARS-CoV-1, thus suggested for further modification as an anti-SARS-CoV agent targeting the viral RNA [88] . Additionally, a β-defensin-based peptide, P9 (33) with sequence NGAICWGPCPTAFRQIGNCGHFKVRCCKIR reportedly exhibits potent antiviral activity against several respiratory viruses including SARS-CoV-1 and MERS-CoV, enhanced by its high binding affinity to the viral glycoproteins and their respective active amino acid residues. The proposed mechanisms of its activities include the effective prevention of endosomal acidification and, blockage of the viral-host membrane fusion and RNA release from late endosomes with IC 50 and TC 50 of 1.2 and 380 µg/mL respectively [89] . where the relative cell fusion reduces to <10% and almost 0% respectively, although the fusion was better blocked in Calu3 than in 293FT cells [8] . Thus, nafamostat deserves further studies for therapeutic development. Similarly, experimental demonstration of the anti-MERS-CoV effect was reported for nitazoxamide (48), an antiviral drug with a broad spectrum of activity. The drug inhibits the viral N-protein expression, suppresses the production of IL-6 and pro-inflammatory cytokines in vivo mice model [96] . The compounds are therefore suggested for further investigation as potential therapeutics against the CoV infections, especially resveratrol whose potentials in combination with indomethacin were proposed as adjuncts for the treatment of SARS-CoV-2 [97] .

As an enveloped, positively-sensed virus with single strands of RNA, MERS-CoV employs S-protein S1 (SS1) subunit to interactively bind to its target receptor, DPP4/CD6 and becomes fused to the plasma/endosomal membrane through a fusion peptide located at Nterminal of S2 subunit. In the S2 site, the heptad repeats 1 (HR1) and the heptad repeats 2 (HR2) bind together to form a 6-helix bundle (6-HB) core for viral-cell membrane fusion. An Amb (5F9) (65) located at the epitope of S1 subunit of MERS-CoV NTD efficiently neutralised the activity of wild-type strain of MERS-CoV, EMC/2012 with quantitative effects in term of IC 50 as 0.2 µg/mL [6] . This supports the scientific argument that antibodies are naturally effective as prophylactic agents and immunotherapy against the onset of CoV infection. For further study, the antibody is available at the National Library of Medicine (https://www.nlm.nih.gov/copyright.html).

Considering the achievable chemotherapeutic concentrations in the targeted human compartments relevant to prognosis and pharmacology of COVID-19 including lung and plasma, Arshad and co-researchers predicted the accumulation of various repurposed drugs in the onset of the viral prevention and treatment within lung tissues using combined physicochemical and pharmacological parameters for modelling. The maximal effective concentrations at 90% (EC 90 ) of the drugs were re-evaluated from in vitro activity records against SARS-CoV-2 expressed in terms of the achievable maximum plasma concentration J o u r n a l P r e -p r o o f (C max ) at an effective dose (C max /EC 90 ratio). Based on the pharmacokinetic parameters within the human plasma and lung, the drug molecules with the highest tendency to exert chemotherapeutic viral suspension were conveniently screened. Those predicted to achieve lung concentrations between 1.5-10-folds higher than the reported EC 50 include amodiaquine (66) , HCQ (67), atazanavir (68), 44, 8, nelfinavir (69), 9 , mefloquine (70) and toremifene (71) with EC 50 of 0.5-4.5 µM (Fig. 10; Scheme 4) . The researchers suggested more focus on the EC 90 evaluation mode and the contextual prioritisation of achievable potentials within the human target compartment such as the lung in further COVID-19 therapeutic studies [101] .

Although, the application of some repurposed antibiotics such as azithromycin in this quest has generated some concerns of microorganism resistance and associated macrolides [102] . [105] . This supports the worthiness of its further study, although, some researchers debate its activity for protection against SARS-CoV-2 infection even in combination with antibiotics such as azithromycin [106] . Although, more robust experimental studies especially clinical and non-clinical in vivo animal/human models are required to reveal details of underlying molecular and cellular mechanisms surrounding the promising efficacy of the agents for the current and emerging CoV strains. Secondly, the study of pharmacodynamics, pharmacokinetics and safety of these candidates are inadequately reported, as such more scientific effort is required especially on the yet-to-be-approved agents. Importantly, this review has not proclaimed the approval of any reported candidate for medical application. However, it reveals the essential therapeutic targets and potent inhibitors amenable for further translational studies into effective pharmaceuticals for the current and emerging CoV infections.

No conflict to declare in this study. (Reproduced from [13] , free access).

J o u r n a l P r e -p r o o f Similarly, nelfinavir was estimated to have higher C max than EC 50 values irrespective of the EC 50 used in the J o u r n a l P r e -p r o o f analysis. The interpretation for other drugs is strongly dependent upon the EC 50 used which is a major concern.

(Reproduced from [101] , Licenced under CC BY-NC-ND 4.0) J o u r n a l P r e -p r o o f

Zika and Other Emerging Viruses: Aiming at the Right Target

To accelerate the Zika beat: Candidate design for RNA interference-based therapy

Drug Weaponry to Fight Against SARS-CoV-2

Hosts and sources of endemic human coronaviruses

The recent outbreaks of human coronaviruses: A medicinal chemistry perspective

A novel neutralizing monoclonal antibody targeting the N-terminal domain of the MERS-CoV spike protein

Coronavirus NL63-induced adult respiratory distress syndrome

Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay

Anti-HCV, nucleotide inhibitors, repurposing against COVID-19

Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion

Active constituents and mechanisms of Respiratory Detox Shot, a traditional Chinese medicine prescription, for COVID-19 control and prevention: network-molecular docking-LC-MSE analysis

COVID-19 for the cardiologist: a current review of the virology, clinical epidemiology, cardiac and other clinical manifestations and potential therapeutic strategies

Map and charts showing the spread of coronavirus

Broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, noroviruses, and coronaviruses

Pathogenesis of Middle East respiratory syndrome coronavirus

Clinical considerations for patients with diabetes in times of COVID-19 epidemic

Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods

COVID-19: Melatonin as a potential adjuvant treatment

The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor-and angiotensin II receptor blocker-based cardiovascular therapies

Povidone-Iodine Demonstrates Rapid In Vitro Virucidal Activity Against SARS-CoV-2, The Virus Causing COVID-19 Disease

Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status

Human coronaviruses: a review of virus-host interactions

Anti-SARS-CoV natural products with the potential to inhibit SARS-CoV-2 (COVID-19)

Bioactive natural compounds against human coronaviruses: a review and perspective

Phage display technique identifies the interaction of severe acute respiratory syndrome coronavirus open reading frame 6 protein with nuclear pore complex interacting protein NPIPB3 in modulating Type I interferon antagonism

A Recovered Case of COVID-19 Myocarditis and ARDS Treated With Corticosteroids, Tocilizumab, and Experimental AT-001

Interaction between RAAS inhibitors and ACE2 in the context of COVID-19

Reninangiotensin-aldosterone system and COVID-19 infection

Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19

Risks of ACE Inhibitor and ARB Usage in COVID-19: Evaluating the Evidence

ACE-inibitori, sartani e sindrome respiratoria acuta da coronavirus 2

Tripartite Combination of Candidate Pandemic Mitigation Agents: Vitamin D, Quercetin, and Estradiol Manifest Properties of Medicinal Agents for Targeted Mitigation of the COVID-19 Pandemic Defined by Genomics-Guided Tracing of SARS-CoV-2 Targets in Human Cells

Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors

Identification of potential inhibitors against SARS-CoV-2 by targeting proteins responsible for envelope formation and virion assembly using docking based virtual screening, and pharmacokinetics approaches

Deamidated Human Triosephosphate Isomerase is a Promising Druggable Target

The Conserved Coronavirus Macrodomain Promotes Virulence and Suppresses the Innate Immune Response during Severe Acute Respiratory Syndrome Coronavirus Infection

Coronavirus nsp10/nsp16 methyltransferase can be targeted by nsp10-derived peptide in vitro and in vivo to reduce replication and pathogenesis

The ns12.9 Accessory Protein of Human Coronavirus OC43 Is a Viroporin Involved in Virion Morphogenesis and Pathogenesis

Identification and characterization of a human coronavirus 229E nonstructural protein 8-associated RNA 3′-terminal adenylyltransferase activity

Role of Severe Acute Respiratory Syndrome Coronavirus Viroporins E, 3a, and 8a in Replication and Pathogenesis

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pancoronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion

Inhibition of Influenza A virus propagation by benzoselenoxanthenes stabilizing TMPRSS2 Gene G-quadruplex and hence downregulating TMPRSS2 expression

Emerging COVID-19 coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26, Emerging microbes & infections

Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib

Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis

Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion

Lessons learned from SARS-CoV and MERS-CoV: FDA-approved Abelson tyrosine-protein kinase 2 inhibitors may help us combat SARS-CoV-2

SARS Unique Domain (SUD) of Severe Acute Respiratory Syndrome Coronavirus Induces NLRP3 Inflammasome-Dependent CXCL10-Mediated Pulmonary Inflammation

Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein

Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants

Potential Inhibitors for Novel Coronavirus Protease Identified by Virtual Screening of 606 Million Compounds

Insights into pediatric multi-system inflammatory syndrome and COVID-19

Purposing Saikosaponins for the treatment of COVID-19

Emetine, Ipecac, Ipecac Alkaloids and Analogues as Potential Antiviral Agents for Coronaviruses

Doxycycline: From Ocular Rosacea

New Insight Into the Coronavirus Outbreak

The endosomal lipid bis(monoacylglycero) phosphate as a potential key player in the mechanism of action of chloroquine against SARS-COV-2 and other enveloped viruses hijacking the endocytic pathway

Chloroquine for the 2019 novel coronavirus SARS-CoV-2

Can hydroxychloroquine protect patients with rheumatic diseases from COVID-19? Response to: 'Does hydroxychloroquine prevent the transmission of COVID-19?' by Heldwein and Calado and 'SLE, hydroxychloroquine and no SLE patients with COVID-19: a comment' by Joob and Wiwanitkit

Teicoplanin: an alternative drug for the treatment of COVID-19?

The old but new: Can unfractioned heparin and low molecular weight heparins inhibit proteolytic activation and cellular internalization of SARS-CoV2 by inhibition of host cell proteases?

Statins in coronavirus outbreak: It's time for experimental and clinical studies

Protein structure analysis of the interactions between SARS-CoV-2 spike protein and the human ACE2 receptor: from conformational changes to novel neutralizing antibodies

Virtual screening and dynamics of potential inhibitors targeting RNA binding domain of nucleocapsid phosphoprotein from SARS-CoV-2

Does lopinavir really inhibit SARS-CoV-2?

Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases

COVID-19 treatment by repurposing drugs until the vaccine is in sight

New therapeutic opportunities for COVID-19 patients with Tocilizumab: Possible correlation of interleukin-6 receptor inhibitors with osteonecrosis of the jaws

Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy

Mesenchymal stem cell infusion shows promise for combating coronavirus (COVID-19)-induced pneumonia

Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients

Chemical composition and pharmacological mechanism of Qingfei Paidu Decoction and Ma Xing Shi Gan Decoction against Coronavirus Disease 2019 (COVID-19): In silico and experimental study

The study on the treatment of Xuebijing injection (XBJ) in adults with severe or critical Corona Virus Disease 2019 and the inhibitory effect of XBJ against SARS-CoV-2

Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-kappaB signaling pathway

COVID-19): first indication of efficacy of Gene-Eden-VIR/Novirin in SARS-CoV-2 infection

Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2)

Aromatic Herbs, Medicinal Plant-Derived Essential Oils, and Phytochemical Extracts as Potential Therapies for Coronaviruses: Future Perspectives

Antibodymediated protection against MERS-CoV in the murine model

Highthroughput screening and identification of potent broad-spectrum inhibitors of coronaviruses

Safe and Sensitive Antiviral Screening Platform Based on Recombinant Human Coronavirus OC43 Expressing the Luciferase Reporter Gene

Structure-based virtual screening and experimental validation of the discovery of inhibitors targeted towards the human coronavirus nucleocapsid protein

siRNA could be a potential therapy for COVID-19

Potent inhibition of feline coronaviruses with peptidyl compounds targeting coronavirus 3C-like protease

Broad-spectrum inhibitors against 3C-like proteases of feline coronaviruses and feline caliciviruses

Reversal of the Progression of Fatal Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus Protease Inhibitor

Virucidal activity of cell-penetrating peptides of viral origin

A novel peptide with potent and broad-spectrum antiviral activities against multiple respiratory viruses

Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA

Antiviral Activity of Extracted Fraction from Camel Urine against Corona and Influenza a (H1n1) Viruses

Treatment With Lopinavir/Ritonavir or Interferon-beta1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

Saracatinib Inhibits Middle East Respiratory Syndrome-Coronavirus Replication In Vitro

Effective inhibition of MERS-CoV infection by resveratrol

Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus

Indomethacin and resveratrol as potential treatment adjuncts for SARS-CoV-2/COVID-19

Protective Effect of Intranasal Regimens Containing Peptidic Middle East Respiratory Syndrome Coronavirus Fusion Inhibitor Against MERS-CoV Infection

Prophylaxis With a Middle East Respiratory Syndrome Coronavirus (MERS-CoV)-Specific Human Monoclonal Antibody Protects Rabbits From MERS-CoV Infection

Ultrapotent Human Neutralizing Antibody Repertoires Against Middle East Respiratory Syndrome Coronavirus From a Recovered Patient

Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics

Use of Azithromycin in COVID-19: A Cautionary Tale

The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro

Combined Prophylactic and Therapeutic Use Maximizes Hydroxychloroquine Anti-SARS-CoV-2 Effects in vitro

Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates

Commentary: Could iron chelators prove to be useful as an adjunct to COVID-19 Treatment Regimens?

Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro

In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2

An Antiviral for Treatment of COVID-19, in Healthy Subjects

In vitro activity of lopinavir/ritonavir and hydroxychloroquine against severe acute respiratory syndrome coronavirus 2 at concentrations achievable by usual doses

Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice

Therapeutic efficacy of Pudilan Xiaoyan Oral Liquid (PDL) for COVID-19 in vitro and in vivo

Roles of flavonoids against coronavirus infection

Sodium chromo-glycate and palmitoylethanolamide: A possible strategy to treat mast cellinduced lung inflammation in COVID-19

The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro

A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2

Chemical structures of some repurposing drugs and their activity against MERS-CoV and SARS-CoVs Scheme 4: Chemical structures of some repurposing drugs and their activity against MERS-CoV and SARS

4: Sequence features of SARS-CoV-2 nucleocapsid protein. (A) The complete genomic features of SARS-CoV-2 Wuhan-Hu-1 isolate (Gene bank: MN908947). UTR = untranslated region

TRS = transcriptional regulatory sequence; orf/ORF = open reading frame

E = envelope protein-encoding region

S = spike glycoprotein encoding region

N = nucleocapsid protein-encoding region

M = membrane protein-encoding region illustrated by Snap Gene Viewer. (B) Domain architectures of CoV N-protein. NTD = N-terminal RNAbinding domain

CTD = C-terminal dimerization domain. (C) Multiple sequence alignment of N-NTD of SARS-CoV-2 with that SARS-CoV (UniProtKB P59595)

Red arrows indicate conserved residues for ribonucleotide binding sites and dash boxes indicate residues variably in structural comparison

Asterisks indicate statistical difference by two-way ANOVA with Turkey's multiple comparison test. (c) Lung hemorrhage 6 dpi for all animals in (a), (b) scored on a scale of 0-4, where 0 is a normal pink healthy lung and 4 is a diffusely discoloured dark red lung. (d) MERS-CoV lung titer 6 dpi in mice as described in (a), (b). Asterisks indicate statistical significance (N group described in (a) and (b), p<0.05) by one-way ANOVA with Kruskal-Wallis test for (c), (d). Data for (a-d) are compiled from two independent experiments

Representative photomicrographs of MERS-CoV antigen (brown) and hematoxylin stained nuclei (blue) in mouse lung tissue sections from 6 dpi. The black bar is 100 µM

Viral titers in rabbit lungs after intravenous prophylaxis with neutralising monoclonal antibody, m336. Rabbits received MERS-CoV-relevant m336 or irrelevant hmAb/m102

Chest radiograph on day 6 with marked improvement in aeration. (E) Chest radiograph on day 8 showing normal lung parenchyma. (F) Computed tomography (CT) of the chest on day 3 revealed extensive diffuse bilateral airspace consolidations and ground-glass opacities most pronounced in the right upper lobe and bilateral lower lobes, with areas of subpleural sparing

Antiviral activity by the cytopathic effect of Vero cells after 48 hours of inoculation with SARS-CoV-2

Positive control; (B) Negative control; (C) 2 µg/mL HCQ, equivalent to PSC of 800 mg once daily; (D) 7:1.75 µg/mL lopinavir/ritonavir, equivalent to PSC of 400/100 mg twice daily

A) Schematic of the recombinant SARS-CoV mouseadapted MA15 strain chimeric virus genomes. SARS/SARS2-RdRp and SARS/SARS2-RdRp-nanoluciferase (nLUC) constructed by exchanging the SARS-CoV-1 MA15 RdRp with the SARS-CoV-2 RdRp. ORF7 is replaced by nLUC in SARS2-RdRp-nLUC. (B) The presence of the SARS-CoV-2 RdRp confirmed by Sanger sequencing in stocks of both recombinant chimeric viruses. The alignment indicates that SARS-CoV-2 RdRpspecific nucleotides are present in both chimeric viruses as shown by the Sanger sequencing and histogram

SARS-CoV-1 replication in Huh7 cells in the presence of remdesivir (left) and associated percentage inhibition (right). (E) Percent starting weight of 17-week-old female Ces1c -l-mice infected intranasally with 1 × 10 3 PFU of SARS/SARS2-RdRp and treated subcutaneously with 25 mg/kg remdesivir or vehicle 1-day post-infection (dpi) and twice daily thereafter. (F) Lung hemorrhage at 5 dpi. (G) Pulmonary function by WBP. The PenH metric shown is a surrogate marker of pulmonary obstruction. p < 0.0001 as determined by two-way ANOVA with Sidak's multiple comparisons test. (H) Lung titer at 5 dpi as measured by plaque assay. p = 0.0012 by Mann-Whitney test

Mohd Nizam Mordi* a a Centre for Drug Research

therapeutic targets and potent inhibitors of some beta-coronaviruses from bench-to-bedside

Halimah Funmilayo Babamale d , Mohd Nizam Mordi* a a Centre for Drug Research